- Home
- BSBK vs BMEA Comparison
BSBK vs BMEA Comparison
Compare BSBK & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSBK
- BMEA
- Stock Information
- Founded
- BSBK 1893
- BMEA 2017
- Country
- BSBK United States
- BMEA United States
- Employees
- BSBK N/A
- BMEA N/A
- Industry
- BSBK Banks
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- BSBK Finance
- BMEA Health Care
- Exchange
- BSBK Nasdaq
- BMEA Nasdaq
- Market Cap
- BSBK 114.0M
- BMEA 125.0M
- IPO Year
- BSBK N/A
- BMEA 2021
- Fundamental
- Price
- BSBK $9.29
- BMEA $2.15
- Analyst Decision
- BSBK
- BMEA Strong Buy
- Analyst Count
- BSBK 0
- BMEA 8
- Target Price
- BSBK N/A
- BMEA $10.63
- AVG Volume (30 Days)
- BSBK 5.2K
- BMEA 658.3K
- Earning Date
- BSBK 10-31-2025
- BMEA 10-28-2025
- Dividend Yield
- BSBK N/A
- BMEA N/A
- EPS Growth
- BSBK N/A
- BMEA N/A
- EPS
- BSBK N/A
- BMEA N/A
- Revenue
- BSBK $14,709,306.00
- BMEA N/A
- Revenue This Year
- BSBK N/A
- BMEA N/A
- Revenue Next Year
- BSBK N/A
- BMEA N/A
- P/E Ratio
- BSBK N/A
- BMEA N/A
- Revenue Growth
- BSBK 16.23
- BMEA N/A
- 52 Week Low
- BSBK $6.59
- BMEA $1.29
- 52 Week High
- BSBK $9.50
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- BSBK 56.86
- BMEA 61.18
- Support Level
- BSBK $8.76
- BMEA $1.98
- Resistance Level
- BSBK $9.38
- BMEA $2.18
- Average True Range (ATR)
- BSBK 0.23
- BMEA 0.12
- MACD
- BSBK -0.03
- BMEA 0.01
- Stochastic Oscillator
- BSBK 71.74
- BMEA 75.76
About BSBK Bogota Financial Corp.
Bogota Financial Corp is a New Jersey-based bank. It offers personal and business banking services such as savings, certificates of deposits, online banking, loans, and many more. The Bank generally grants residential, commercial, and consumer loans to, and accepts deposits from customers in New Jersey.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.